Two Poster Presentations Will Feature Updated
Ivonescimab Data from the AK112-201 and AK112-202 Phase II Studies
in Advanced or Metastatic NSCLC Patient Populations
Posters to be Presented by Dr. Li Zhang and Dr.
Jack West on Friday, March 22 in Prague
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the
“Company”) today announced that data for its novel, potential
first-in-class investigational bispecific antibody, ivonescimab,
will be presented at the 2024 European Lung Cancer Congress (ELCC
2024) in Prague, Czech Republic. Two posters featuring updated
ivonescimab data will be displayed on Friday, March 22 from 12:00
to 12:45pm Central European Time.
The first poster, “Intracranial Activity of Ivonescimab Alone or
in Combination with Platinum Doublet Chemotherapy in Patients with
Advanced Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases”
includes data from patients with asymptomatic brain metastases at
baseline. These patients were enrolled in either AK112-202
(NCT04900363), in which ivonescimab is delivered as monotherapy, or
AK112-201 (NCT04736823), in which ivonescimab is delivered in
combination with platinum doublet chemotherapy, both of which are
Phase II clinical trials for patients with advanced or metastatic
NSCLC.
The second poster titled, “Phase 2 Results of Ivonescimab a
Novel PD-1/VEGF Bispecific in Combination with Chemotherapy for
First Line Treatment of Patients with Advanced / Metastatic
Squamous Non-Small Cell Lung Cancer” includes updated data from the
Phase II trial AK112-201 centered around the cohort of patients in
which ivonescimab is combined with chemotherapy for first line
treatment of advanced or metastatic NSCLC in patients without
actionable genomic alterations (e.g., positive for endothelial
growth factor receptor (EGFR) mutations or anaplastic lymphoma
kinase (ALK)).
The posters will be presented by, amongst others, Dr. Li Zhang,
Sun Yat-Sen University Cancer Center, and Dr. H. Jack West, Vice
President of Clinical Development at Summit with data generated and
analyzed by our collaboration and licensing partner, Akeso Inc.
(HKEX Code: 9926.HK), with contribution by Summit staff.
Summit continues its clinical development of ivonescimab in
order to establish its efficacy and safety in two NSCLC
indications:
- HARMONi Phase III trial: ivonescimab combined with chemotherapy
in patients with epidermal growth factor receptor (EGFR)-mutated,
locally advanced or metastatic non-squamous NSCLC who have
progressed after treatment with a third-generation EGFR tyrosine
kinase inhibitor (TKI)
- HARMONi-3 Phase III trial: ivonescimab combined with
chemotherapy in first-line metastatic squamous NSCLC patients
About the ELCC 2024 Posters
Poster Title: Phase 2 Results of Ivonescimab a Novel PD-1/VEGF
Bispecific in Combination with Chemotherapy for First Line
Treatment of Patients with Advanced / Metastatic Squamous Non-Small
Cell Lung Cancer (NSCLC) ELCC Presentation No.: 68P Session Date
& Time: Friday, March 22, 12:00 to 12:45pm CET
Poster Title: Intracranial Activity of Ivonescimab Alone or in
Combination with Platinum Doublet Chemotherapy in Patients with
Advanced Non-Small Cell Lung Cancer and Brain Metastases ELCC
Presentation No.: 174P Session Date & Time: Friday, March 22,
12:00 to 12:45pm CET
About Ivonescimab
Ivonescimab, known as SMT112 in Summit’s license territories,
the United States, Canada, Europe, and Japan, and as AK112 in China
and Australia, is an investigational, novel, potential
first-in-class bispecific antibody combining the effects of
immunotherapy via a blockade of PD-1 with the anti-angiogenesis
effects associated with blocking VEGF into a single molecule.
Ivonescimab displays cooperative binding with each of its intended
targets with higher affinity when in the presence of both PD-1 and
VEGF.
This could differentiate ivonescimab as there is potentially
higher expression (presence) of both PD-1 and VEGF in tumor tissue
and the tumor microenvironment (TME) as compared to normal tissue
in the body. Ivonescimab’s tetravalent structure (four binding
sites) enables higher avidity (accumulated strength of multiple
binding interactions) in the tumor microenvironment with over
18-fold increased binding affinity to PD-1 in the presence of VEGF
in vitro, and over 4-times increased binding affinity to VEGF in
the presence of PD-1 in vitro (Zhong, et al, SITC, 2023). This
tetravalent structure, the intentional novel design of the
molecule, and bringing these two targets into a single bispecific
antibody with cooperative binding qualities have the potential to
direct ivonescimab to the tumor tissue versus healthy tissue. The
intent of this design is to improve upon previously established
efficacy thresholds, in addition to side effects and safety
profiles associated with these targets.
Ivonescimab was discovered by Akeso Inc. (HKEX Code: 9926.HK)
and is currently engaged in multiple Phase III clinical trials.
Over 1,600 patients have been treated with ivonescimab in clinical
studies globally. Summit has begun its clinical development of
ivonescimab in non-small cell lung cancer (NSCLC), commencing
enrollment in 2023 in two Phase III clinical trials.
Ivonescimab is an investigational therapy that is not approved
by any regulatory authority.
About Summit Therapeutics
Summit was founded in 2003 and our shares are listed on the
Nasdaq Global Market (symbol ‘SMMT’). We are headquartered in
Miami, Florida, and we have additional offices in Menlo Park,
California, and Oxford, UK.
Summit’s mission, in part, is to develop patient, physician,
caregiver, and societal-friendly medicinal therapies intended to
improve quality of life, increase potential duration of life, and
resolve serious unmet medical needs.
For more information, please visit https://www.smmttx.com and
follow us on X (formerly Twitter) @summitplc.
Summit Forward-looking Statements
Any statements in this press release about the Company’s future
expectations, plans and prospects, including but not limited to,
statements about the clinical and preclinical development of the
Company’s product candidates, entry into and actions related to the
Company’s partnership with Akeso Inc., the Company's anticipated
spending and cash runway, the therapeutic potential of the
Company’s product candidates, the potential commercialization of
the Company’s product candidates, the timing of initiation,
completion and availability of data from clinical trials, the
potential submission of applications for marketing approvals,
potential acquisitions, and other statements containing the words
"anticipate," "believe," "continue," "could," "estimate," "expect,"
"intend," "may," "plan," "potential," "predict," "project,"
"should," "target," "would," and similar expressions, constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including the results of
our evaluation of the underlying data in connection with the
development and commercialization activities for ivonescimab, the
outcome of discussions with regulatory authorities, including the
Food and Drug Administration, the uncertainties inherent in the
initiation of future clinical trials, availability and timing of
data from ongoing and future clinical trials, the results of such
trials, and their success, and global public health crises, that
may affect timing and status of our clinical trials and operations,
whether preliminary results from a clinical trial will be
predictive of the final results of that trial or whether results of
early clinical trials or preclinical studies will be indicative of
the results of later clinical trials, whether business development
opportunities to expand the Company’s pipeline of drug candidates,
including without limitation, through potential acquisitions of,
and/or collaborations with, other entities occur, expectations for
regulatory approvals, laws and regulations affecting government
contracts and funding awards, availability of funding sufficient
for the Company’s foreseeable and unforeseeable operating expenses
and capital expenditure requirements and other factors discussed in
the "Risk Factors" section of filings that the Company makes with
the Securities and Exchange Commission. Any change to our ongoing
trials could cause delays, affect our future expenses, and add
uncertainty to our commercialization efforts, as well as to affect
the likelihood of the successful completion of clinical development
of ivonescimab. Accordingly, readers should not place undue
reliance on forward-looking statements or information. In addition,
any forward-looking statements included in this press release
represent the Company’s views only as of the date of this release
and should not be relied upon as representing the Company’s views
as of any subsequent date. The Company specifically disclaims any
obligation to update any forward-looking statements included in
this press release.
Appendix: Glossary of Critical Terms Contained Herein
Affinity – Affinity is the strength of binding of a
molecule, such as a protein or antibody, to another molecule, such
as a ligand.
Avidity – Avidity is the accumulated strength of multiple
binding interactions.
Angiogenesis – Angiogenesis is the development,
formation, and maintenance of blood vessel structures. Without
sufficient blood flow, tissue may experience hypoxia (insufficient
oxygen) or lack of nutrition, which may cause cell death.i
Cooperative binding – Cooperative binding occurs when the
number of binding sites on the molecule that can be occupied by a
specific ligand (e.g., protein) is impacted by the ligand’s
concentration. For example, this can be due to an affinity for the
ligand that depends on the amount of ligand bound or the binding
strength of the molecule to one ligand based on the concentration
of another ligand, increasing the chance of another ligand binding
to the compound.ii
Immunotherapy – Immunotherapy is a type of treatment,
including cancer treatments, that help a person’s immune system
fight cancer. Examples include anti-PD-1 therapies.iii
Intracranial – Within the cranium or skull.
PD-1 – Programmed cell
Death protein 1 is a protein on the surface of T cells and other
cells. PD-1 plays a key role in reducing the regulation of
ineffective or harmful immune responses and maintaining immune
tolerance. However, with respect to cancer tumor cells, PD-1 can
act as a stopping mechanism (a brake or checkpoint) by binding to
PD-L1 ligands that exist on tumor cells and preventing the T cells
from targeting cancerous tumor cells.iv
PD-L1 – Programmed cell
Death Ligand 1 is expressed
by cancerous tumor cells as an adaptive immune mechanism to escape
anti-tumor responses, thus believed to suppress the immune system’s
response to the presence of cancer cells. v
PD-L1 TPS – PD-L1 Tumor
Proportion Score represents the percentage of tumor cells
that express PD-L1 proteins.
PFS – Progression-Free
Survival.
SQ-NSCLC – Non-small cell lung cancer tumors of squamous
histology.
T Cells – T cells are a type of white blood cell that is
a component of the immune system that, in general, fights against
infection and harmful cells like tumor cells.vi
Tetravalent – A tetravalent molecule has four binding
sites or regions.
Tumor Microenvironment – The tumor microenvironment is
the ecosystem that surrounds a tumor inside the body. It includes
immune cells, the extracellular matrix, blood vessels and other
cells, like fibroblasts. A tumor and its microenvironment
constantly interact and influence each other, either positively or
negatively.vii
VEGF – Vascular Endothelial Growth
Factor is a signaling protein that
promotes angiogenesis.viii
___________________________________
i Shibuya M. Vascular Endothelial Growth Factor (VEGF) and Its
Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for
Anti- and Pro-Angiogenic Therapies. Genes Cancer. 2011
Dec;2(12):1097-105. ii Stefan MI, Le Novère N. Cooperative binding.
PLoS Comput Biol. 2013;9(6) iii US National Cancer Institute, a
part of the National Institute of Health (NIH).
https://www.cancer.gov/about-cancer/treatment/types/immunotherapy.
Accessed October 2023. iv Han Y, et al. PD-1/PD-L1 Pathway: Current
Researches in Cancer. Am J Cancer Res. 2020 Mar 1;10(3):727-742. v
Han Y, et al. PD-1/PD-L1 Pathway: Current Researches in Cancer. Am
J Cancer Res. 2020 Mar 1;10(3):727-742. vi Cleveland Clinic.
https://my.clevelandclinic.org/health/body/24630-t-cells. Accessed
October 2023. vii MD Anderson Cancer Center.
https://www.mdanderson.org/cancerwise/what-is-the-tumor-microenvironment-3-things-to-know.h00-159460056.html.
Accessed October 2023. viii Shibuya M. Vascular Endothelial Growth
Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A
Crucial Target for Anti- and Pro-Angiogenic Therapies. Genes
Cancer. 2011 Dec;2(12):1097-105.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240314799272/en/
Contact Summit Investor Relations: Dave Gancarz Chief
Business & Strategy Officer
Nathan LiaBraaten Senior Director, Investor Relations
investors@smmttx.com
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From May 2024 to Jun 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jun 2023 to Jun 2024